Henry H Ruiz1, Tiffany Chi1, Andrew C Shin1, Claudia Lindtner1, Wilson Hsieh1, Michelle Ehrlich2, Sam Gandy3, Christoph Buettner4. 1. Department of Medicine, Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Department of Neurology and Pediatrics, Mount Sinai School of Medicine, New York, NY, USA. 3. Department of Neurology, Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York, NY, USA; Department of Psychiatry, Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York, NY, USA. 4. Department of Medicine, Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: christoph.buettner@mssm.edu.
Abstract
INTRODUCTION: Epidemiologic studies have demonstrated an association between diabetes and dementia. Insulin signaling within the brain, in particular within the hypothalamus regulates carbohydrate, lipid, and branched chain amino acid (BCAA) metabolism in peripheral organs such as the liver and adipose tissue. We hypothesized that cerebral amyloidosis impairs central nervous system control of metabolism through disruption of insulin signaling in the hypothalamus, which dysregulates glucose and BCAA homeostasis resulting in increased susceptibility to diabetes. METHODS: We examined whether APP/PS1 mice exhibit increased susceptibility to aging or high-fat diet (HFD)-induced metabolic impairment using metabolic phenotyping and insulin-signaling studies. RESULTS: APP/PS1 mice were more susceptible to high-fat feeding and aging-induced metabolic dysregulation including disrupted BCAA homeostasis and exhibited impaired hypothalamic insulin signaling. DISCUSSION: Our data suggest that AD pathology increases susceptibility to diabetes due to impaired hypothalamic insulin signaling, and that plasma BCAA levels could serve as a biomarker of hypothalamic insulin action in patients with AD.
INTRODUCTION: Epidemiologic studies have demonstrated an association between diabetes and dementia. Insulin signaling within the brain, in particular within the hypothalamus regulates carbohydrate, lipid, and branched chain amino acid (BCAA) metabolism in peripheral organs such as the liver and adipose tissue. We hypothesized that cerebral amyloidosis impairs central nervous system control of metabolism through disruption of insulin signaling in the hypothalamus, which dysregulates glucose and BCAA homeostasis resulting in increased susceptibility to diabetes. METHODS: We examined whether APP/PS1mice exhibit increased susceptibility to aging or high-fat diet (HFD)-induced metabolic impairment using metabolic phenotyping and insulin-signaling studies. RESULTS:APP/PS1mice were more susceptible to high-fat feeding and aging-induced metabolic dysregulation including disrupted BCAA homeostasis and exhibited impaired hypothalamic insulin signaling. DISCUSSION: Our data suggest that AD pathology increases susceptibility to diabetes due to impaired hypothalamic insulin signaling, and that plasma BCAA levels could serve as a biomarker of hypothalamic insulin action in patients with AD.
Authors: Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold Journal: J Clin Invest Date: 2012-04 Impact factor: 14.808
Authors: Mikko Hiltunen; Vinoth K M Khandelwal; Nagendra Yaluri; Tea Tiilikainen; Maija Tusa; Henna Koivisto; Marine Krzisch; Saila Vepsäläinen; Petra Mäkinen; Susanna Kemppainen; Pasi Miettinen; Annakaisa Haapasalo; Hilkka Soininen; Markku Laakso; Heikki Tanila Journal: J Cell Mol Med Date: 2012-06 Impact factor: 5.310
Authors: Michael V Morabito; Diego E Berman; Remy T Schneider; Yiying Zhang; Rudolph L Leibel; Scott A Small Journal: Neurobiol Dis Date: 2014-01-14 Impact factor: 5.996
Authors: Michael P Bancks; Alvaro Alonso; Rebecca F Gottesman; Thomas H Mosley; Elizabeth Selvin; James S Pankow Journal: Alzheimers Dement Date: 2017-06-16 Impact factor: 21.566
Authors: Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan Journal: Nat Rev Neurol Date: 2018-01-29 Impact factor: 42.937
Authors: Jon B Toledo; Matthias Arnold; Gabi Kastenmüller; Rui Chang; Rebecca A Baillie; Xianlin Han; Madhav Thambisetty; Jessica D Tenenbaum; Karsten Suhre; J Will Thompson; Lisa St John-Williams; Siamak MahmoudianDehkordi; Daniel M Rotroff; John R Jack; Alison Motsinger-Reif; Shannon L Risacher; Colette Blach; Joseph E Lucas; Tyler Massaro; Gregory Louie; Hongjie Zhu; Guido Dallmann; Kristaps Klavins; Therese Koal; Sungeun Kim; Kwangsik Nho; Li Shen; Ramon Casanova; Sudhir Varma; Cristina Legido-Quigley; M Arthur Moseley; Kuixi Zhu; Marc Y R Henrion; Sven J van der Lee; Amy C Harms; Ayse Demirkan; Thomas Hankemeier; Cornelia M van Duijn; John Q Trojanowski; Leslie M Shaw; Andrew J Saykin; Michael W Weiner; P Murali Doraiswamy; Rima Kaddurah-Daouk Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 16.655
Authors: Luke E Stoeckel; Zoe Arvanitakis; Sam Gandy; Dana Small; C Ronald Kahn; Alvaro Pascual-Leone; Aaron Pawlyk; Robert Sherwin; Philip Smith Journal: F1000Res Date: 2016-03-15
Authors: Elysse M Knight; Henry H Ruiz; Soong Ho Kim; Jessica C Harte; Wilson Hsieh; Charles Glabe; William L Klein; Alan D Attie; Christoph Buettner; Michelle E Ehrlich; Sam Gandy Journal: Acta Neuropathol Commun Date: 2016-02-25 Impact factor: 7.801